In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2018 Mar 31

PMID 29601486

Citations 30

Authors

Blessing Atim Aderibigbe

Affiliations

Soon will be listed here.

Abstract

In situ-based gel drug delivery systems that can bypass the blood-brain barrier, deliver the therapeutics to the desired site, reduce peripheral toxicity and control drug release kinetics have been developed. Some of the therapeutics used to treat neurological diseases suffer from poor bioavailability. Preclinical reports from several researchers have proven that the delivery of drugs to the brain via the nose-to-brain route using in situ gels holds great promise. However, safety issues on the toxicity of the nasal mucosa, transportation of the drugs to specific brain regions and determination of the required dose are factors that must be considered when designing these gels. This review will be focused on in situ-based gels that are used for the delivery of therapeutics via the nose-to-brain route, preclinical reports and challenges.

Citing Articles

Intranasal Mucoadhesive In Situ Gel of Glibenclamide-Loaded Bilosomes for Enhanced Therapeutic Drug Delivery to the Brain.

Tripathi M, Gharti L, Bansal A, Kaurav H, Sheth S Pharmaceutics. 2025; 17(2).

PMID: 40006560 PMC: 11859129. DOI: 10.3390/pharmaceutics17020193.

In Situ Thermosensitive Mucoadhesive Nasal Gel Containing Sumatriptan: and Evaluations.

Alshraim A, Alshora D, Ashri L, Alhusaini A, Alanazi N, Safwan N Polymers (Basel). 2024; 16(23).

PMID: 39684167 PMC: 11644292. DOI: 10.3390/polym16233422.

Development and Optimization of Nasal Composition of a Neuroprotective Agent for Use in Neonatology after Prenatal Hypoxia.

Belenichev I, Aliyeva O, Burlaka B, Burlaka K, Kuchkovskyi O, Savchenko D Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204095 PMC: 11356968. DOI: 10.3390/ph17080990.

Preparation, , and Pharmacokinetic Study of Lasmiditan as Intranasal Nanoemulsion-based Gel.

Jabir S, Jaber S, Rajab N Pharm Nanotechnol. 2024; 13(1):239-253.

PMID: 38173066 DOI: 10.2174/0122117385285009231222072303.

Ion-activated Gel of Gellan Gum Containing Chrysin for Nasal Administration in Parkinson's Disease.

Lavania K, Garg A Recent Adv Drug Deliv Formul. 2023; 18(1):35-49.

PMID: 38058093 DOI: 10.2174/0126673878279656231204103855.

References

Illum L . Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci. 2000; 11(1):1-18. DOI: 10.1016/s0928-0987(00)00087-7. View

Compston A, Coles A . Multiple sclerosis. Lancet. 2008; 372(9648):1502-17. DOI: 10.1016/S0140-6736(08)61620-7. View

Sosnik A, Seremeta K . Polymeric Hydrogels as Technology Platform for Drug Delivery Applications. Gels. 2019; 3(3). PMC: 6318675. DOI: 10.3390/gels3030025. View

Wang Y, Jiang S, Wang H, Bie H . A mucoadhesive, thermoreversible in situ nasal gel of geniposide for neurodegenerative diseases. PLoS One. 2017; 12(12):e0189478. PMC: 5730156. DOI: 10.1371/journal.pone.0189478. View

Dhuria S, Hanson L, Frey 2nd W . Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2009; 99(4):1654-73. DOI: 10.1002/jps.21924. View

. FDA-approved drugs to treat schizophrenia. J Psychosoc Nurs Ment Health Serv. 2014; 52(12):11-2. DOI: 10.3928/02793695-20141029-79. View

Silberberg D, Anand N, Michels K, Kalaria R . Brain and other nervous system disorders across the lifespan - global challenges and opportunities. Nature. 2015; 527(7578):S151-4. DOI: 10.1038/nature16028. View

Khan S, Patil K, Bobade N, Yeole P, Gaikwad R . Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J Drug Target. 2009; 18(3):223-34. DOI: 10.3109/10611860903386938. View

Galgatte U, Kumbhar A, Chaudhari P . Development of in situ gel for nasal delivery: design, optimization, in vitro and in vivo evaluation. Drug Deliv. 2013; 21(1):62-73. DOI: 10.3109/10717544.2013.849778. View

10.

Kumar R, Bhave A, Bhargava R, Agarwal G . Prevalence and risk factors for neurological disorders in children aged 6 months to 2 years in northern India. Dev Med Child Neurol. 2013; 55(4):348-56. DOI: 10.1111/dmcn.12079. View

11.

Wong H, Wu X, Bendayan R . Nanotechnological advances for the delivery of CNS therapeutics. Adv Drug Deliv Rev. 2011; 64(7):686-700. DOI: 10.1016/j.addr.2011.10.007. View

12.

Aseervatham G S, Choi S, Krishnan J, K R . Cigarette smoke and related risk factors in neurological disorders: An update. Biomed Pharmacother. 2016; 85:79-86. DOI: 10.1016/j.biopha.2016.11.118. View

13.

LeWitt P . Levodopa for the treatment of Parkinson's disease. N Engl J Med. 2008; 359(23):2468-76. DOI: 10.1056/NEJMct0800326. View

14.

Krol S . Challenges in drug delivery to the brain: nature is against us. J Control Release. 2012; 164(2):145-55. DOI: 10.1016/j.jconrel.2012.04.044. View

15.

Van Woensel M, Wauthoz N, Rosiere R, Amighi K, Mathieu V, Lefranc F . Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?. Cancers (Basel). 2013; 5(3):1020-48. PMC: 3795377. DOI: 10.3390/cancers5031020. View

16.

Chen X, Zhi F, Jia X, Zhang X, Ambardekar R, Meng Z . Enhanced brain targeting of curcumin by intranasal administration of a thermosensitive poloxamer hydrogel. J Pharm Pharmacol. 2013; 65(6):807-16. DOI: 10.1111/jphp.12043. View

17.

Tao T, Zhao Y, Yue P, Dong W, Chen Q . [Preparation of huperzine A nasal in situ gel and evaluation of its brain targeting following intranasal administration]. Yao Xue Xue Bao. 2007; 41(11):1104-10. View

18.

Haque S, Md S, Sahni J, Ali J, Baboota S . Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression. J Psychiatr Res. 2013; 48(1):1-12. DOI: 10.1016/j.jpsychires.2013.10.011. View

19.

Kanwar J, Sriramoju B, Kanwar R . Neurological disorders and therapeutics targeted to surmount the blood-brain barrier. Int J Nanomedicine. 2012; 7:3259-78. PMC: 3405884. DOI: 10.2147/IJN.S30919. View

20.

Fatouh A, Elshafeey A, Abdelbary A . Agomelatine-based in situ gels for brain targeting via the nasal route: statistical optimization, in vitro, and in vivo evaluation. Drug Deliv. 2017; 24(1):1077-1085. PMC: 8241098. DOI: 10.1080/10717544.2017.1357148. View